Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT5 | Q92993 | 3/20 | 0.38 |
| ▸ | KAT6A | Q92794 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.36 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.35 |
| ▸ | FEN1 | P39748 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23893336 | 0.92 | PDE4B (0.38) | KAT5KAT6AKAT8USP30EHMT2 | |
| SCHEMBL9929683 | 0.92 | PDE4B (0.38) | KAT5KAT6AKAT8USP30EHMT2 | |
| SCHEMBL9929332 | 0.91 | KAT5 (0.37) | KAT5KAT6AKAT8USP30PDE4B | |
| SCHEMBL14736072 | 0.90 | PIK3CD (0.42) | KAT5KAT6AALDH1A1NPC1MAPT | |
| SCHEMBL29836193 | 0.90 | PIK3CD (0.42) | KAT5KAT6AALDH1A1NPC1MAPT | |
| SCHEMBL29510792 | 0.89 | ALDH1A1 (0.39) | ALDH1A1NPC1MAPTMAPK1HTT | |
| SCHEMBL14736963 | 0.89 | ALDH1A1 (0.39) | ALDH1A1NPC1MAPTMAPK1HTT | |
| SCHEMBL14735938 | 0.88 | PIK3CD (0.41) | ALDH1A1NPC1MAPTMAPK1HTT | |
| SCHEMBL9928910 | 0.86 | EIF4A3 (0.32) | — | |
| SCHEMBL9929063 | 0.83 | KAT5 (0.39) | KAT5KAT6AMAPTKAT8USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250325550-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORP (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250289823-A1 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K-DELTA RELATED DISORDERS | INCYTE CORPORATION | 2025-09-18 | — | — | US | disclosed |
| EP-3888657-B1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE HOLDINGS CORP (US) | 2025-03-19 | — | — | EP | disclosed |
| US-12201636-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE CORPORATION (US) | 2025-01-21 | — | — | US | disclosed |
| US-12152033-B2 | Use of pyrazolopyrimidine derivatives for the treatment of PI3K-δ related disorders | INCYTE CORPORATION (US) | 2024-11-26 | — | — | US | disclosed |
| US-20240216377-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2024-07-04 | — | — | US | disclosed |
| US-20240216377-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2024-07-04 | — | — | US | disclosed |
| US-20240216377-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2024-07-04 | — | — | US | disclosed |
| US-11819505-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE CORPORATION (US) | 2023-11-21 | — | — | US | disclosed |
| US-11819505-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE CORPORATION (US) | 2023-11-21 | — | — | US | disclosed |
| US-9199982-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2015-12-01 | — | — | US | disclosed |
| US-9199982-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2015-12-01 | — | — | US | disclosed |
| US-9199982-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2015-12-01 | — | — | US | disclosed |
| US-20150284390-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2015-10-08 | — | — | US | disclosed |
| US-9096600-B2 | N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors | INCYTE CORPORATION (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140249132-A1 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K-DELTA RELATED DISORDERS | INCYTE CORPORATION (US) | 2014-09-04 | — | — | US | disclosed |
| US-20130059835-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130059835-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130059835-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2013-03-07 | — | — | US | disclosed |
| US-20120157430-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249132-A1 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K-DELTA RELATED DISORDERS | PIK3CD, PIK3CA, PIK3CB | KAT5 4034/4885KAT6A 2630/4885ALDH1A1 2442/4885 |
| US-20250325550-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | KAT5 1083/4885KAT6A 930/4885ALDH1A1 3232/4885 |
| US-20120157430-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PI4KB | KAT5 3879/4885KAT6A 959/4885ALDH1A1 3828/4885 |
| US-20240216377-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | KAT5 1083/4885KAT6A 930/4885ALDH1A1 3232/4885 |
| US-12152033-B2 | Use of pyrazolopyrimidine derivatives for the treatment of PI3K-δ related disorders | PIK3CD, PIK3CA, PIK3R5 | KAT5 3872/4885KAT6A 2302/4885ALDH1A1 2698/4885 |
| US-11819505-B2 | Heterocyclylamines as PI3K inhibitors | PIK3CA, PIK3CD, PIK3CB | KAT5 1083/4885KAT6A 930/4885ALDH1A1 3232/4885 |
| US-20150284390-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PI4KB | KAT5 3879/4885KAT6A 959/4885ALDH1A1 3828/4885 |
| US-20250289823-A1 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K-DELTA RELATED DISORDERS | PIK3CD, PIK3CA, PIK3CB | KAT5 4034/4885KAT6A 2630/4885ALDH1A1 2442/4885 |
| US-12201636-B2 | Heterocyclylamines as PI3K inhibitors | PIK3CA, PIK3CD, PIK3CB | KAT5 1083/4885KAT6A 930/4885ALDH1A1 3232/4885 |
| US-20130059835-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | KAT5 1083/4885KAT6A 930/4885ALDH1A1 3232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.